

=> dis his

(FILE 'HOME' ENTERED AT 15:31:39 ON 29 FEB 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'  
ENTERED AT 15:31:58 ON 29 FEB 2004

L1 28602 S (ALPHA-1-ACID GLYCOPROTEIN OR AAG OR OROSMUCOID OR ACUTE PLAS  
L2 3371 S L1 AND (LIPOPOLYSACCHARIDE OR LPS OR ENDOTOXIN#)  
L3 3076 S L2 AND (REMOV? OR PURIF? OR PREPAR? OR DEPYROGEN?)  
L4 2076 S L3 AND (RESIN OR SILICA-BASED OR FUMED SILICA OR HYDROPHIL?)  
L5 2062 S L4 AND (VIR? INACTIVAT? OR TREAT? OR DISINFECT?)  
L6 1521 S L5 AND (REMOV? ENDOTOXIN OR LIPOPOLYSACCHARIDE OR LPS)  
L7 1446 S L6 AND (ANION EXCHANGE MATRIX OR CHROMATOG?)  
L8 4 S L7 AND (ANION EXCHANGE MATRIX)  
L9 1446 S L7 AND (DEPYROGENAT? OR INACTIVAT? OR TREAT?)  
L10 5 S L9 AND (COHN FRACTION?)  
L11 5 DUP REM L10 (0 DUPLICATES REMOVED)  
L12 1057 S L9 AND (FILTRAT? OR PASTEURIZ?)  
L13 781 S L12 AND (RESIN)  
L14 780 S REMOV? AND L13  
L15 22 S DEPYROGEN? AND L14  
L16 2 S L8 AND L15  
L17 2 S L10 AND L15  
L18 2 S L16 AND L17  
L19 2 S L16 AND (DRUG TOXIC?)

=> dup rem l15

PROCESSING COMPLETED FOR L15

L20 22 DUP REM L15 (0 DUPLICATES REMOVED)

=> s l20 and (medica? or therap?)

6 FILES SEARCHED...

L21 22 L20 AND (MEDICA? OR THERAP?)

=> s l21 and (0.050 Eu/mg or 01. Eu/mg or 0.075 Eu/mg)

'MG' IS NOT A VALID FIELD CODE

'MG' IS NOT A VALID FIELD CODE

'MG' IS NOT A VALID FIELD CODE

'MG' IS NOT A VALID FIELD CODE

'MG' IS NOT A VALID FIELD CODE

'MG' IS NOT A VALID FIELD CODE

'MG' IS NOT A VALID FIELD CODE

L22 0 L21 AND (0.050 EU/MG OR 01. EU/MG OR 0.075 EU/MG)

=> s l21 and (concentrat?)

L23 22 L21 AND (CONCENTRAT?)

=> s l23 and (0.1 or 0.075 or 0.050)

6 FILES SEARCHED...

L24 22 L23 AND (0.1 OR 0.075 OR 0.050)

=> s l24 and (virus deplet? or virus inactivat?)

L25 2 L24 AND (VIRUS DEPLET? OR VIRUS INACTIVAT?)

=> d l25 1-2 bib ab

L25 ANSWER 1 OF 2 USPATFULL on STN

AN 2002:235983 USPATFULL

TI Purification method

IN More, John Edward, Elstree, UNITED KINGDOM

Rott, Jacqueline, Elstree, UNITED KINGDOM

Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority (non-U.S. corporation)

PI US 2002128180 A1 20020912

AI US 2002-82925 A1 20020226 (10)  
RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A  
371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997,  
UNKNOWN  
PRAI GB 1996-4921 19960308  
DT Utility  
FS APPLICATION  
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS,  
MN, 55402  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of **removing**  
**endotoxin** from **preparation** of **alpha-**  
**1-acid glycoprotein** (orosomucoid) by contact  
with a finely divided non-toxic **resin** such as **fumed**  
**silica**. The invention also relates to a **purification**  
process for **alpha-1-acid**  
**glycoprotein** which includes this **depyrogenation** step,  
and to the **depyrogenated** product and its clinical uses.

L25 ANSWER 2 OF 2 USPATFULL on STN

AN 2002:109017 USPATFULL

TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM  
Rott, Jacqueline, Elstree, UNITED KINGDOM  
Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)

PI US 6387877 B1 20020514  
WO 9732893 19970912

AI US 1999-142348 19990125 (9)  
WO 1997-GB642 19970307  
19990125 PCT 371 date

PRAI DE 1996-4921 19960308

DT Utility

FS GRANTED

EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed,  
Abdel A.

LREP Schwegman, Lundberg, Woessner & Kluth, P.A.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of **removing**  
**endotoxin** from **preparations** of **alpha-**  
**1-acid glycoprotein** (orosomucoid) by contact  
with a finely divided non-toxic **resin** such as **fumed**  
**silica**. The invention also relates to a **purification**  
process for **alpha-1-acid**  
**glycoprotein** which includes this **depyrogenation** step, and to the  
**depyrogenated** product and its clinical uses.

=> d 124 1-5 bib ab

L24 ANSWER 1 OF 22 USPATFULL on STN

AN 2003:311862 USPATFULL

TI Soluble recombinant botulinum toxins

IN Williams, James A., Madison, WI, UNITED STATES

PA Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES,  
92612 (U.S. corporation)

PI US 2003219457 A1 20031127

AI US 2002-271012 A1 20021015 (10)  
RLI Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING  
Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995,  
GRANTED, Pat. No. US 5919665  
DT Utility  
FS APPLICATION  
LREP STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN 40 Drawing Page(s)  
LN.CNT 16361

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes recombinant proteins derived from  
Clostridium botulinum toxins. In particular, soluble recombinant  
Clostridium botulinum type A, type B and type E toxin proteins are  
provided. Methods which allow for the isolation of recombinant proteins  
free of significant **endotoxin** contamination are provided. The  
soluble, **endotoxin**-free recombinant proteins are used as  
immunogens for the production of vaccines and antitoxins. These vaccines  
and antitoxins are useful in the **treatment** of humans and other  
animals at risk of intoxication with clostridial toxin.

L24 ANSWER 2 OF 22 USPATFULL on STN

AN 2003:306036 USPATFULL  
TI Soluble recombinant botulinum toxin proteins  
IN Williams, James A., Madison, WI, UNITED STATES  
Thalley, Bruce S., Madison, WI, UNITED STATES  
PA Allergan, Inc., Allergan Botox Limited, Irvine, CA, 92612 (U.S.  
corporation)  
PI US 2003215468 A1 20031120  
AI US 2003-354774 A1 20030130 (10)  
RLI Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING  
Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995,  
GRANTED, Pat. No. US 5919665  
DT Utility  
FS APPLICATION  
LREP STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN 40 Drawing Page(s)  
LN.CNT 16347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes recombinant proteins derived from  
Clostridium botulinum toxins. In particular, soluble recombinant  
Clostridium botulinum type A, type B and type E toxin proteins are  
provided. Methods which allow for the isolation of recombinant proteins  
free of significant **endotoxin** contamination are provided. The  
soluble, **endotoxin**-free recombinant proteins are used as  
immunogens for the production of vaccines and antitoxins. These vaccines  
and antitoxins are useful in the **treatment** of humans and other  
animals at risk of intoxication with clostridial toxin.

L24 ANSWER 3 OF 22 USPATFULL on STN

AN 2003:299854 USPATFULL  
TI Combined compositions for tumor vasculature coagulation and  
**treatment**  
IN Thorpe, Philip E., Dallas, TX, UNITED STATES  
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES  
Gottstein, Claudia, Dallas, TX, UNITED STATES  
PI US 2003211075 A1 20031113  
AI US 2002-259244 A1 20020927 (10)  
PRAI US 2001-325532P 20010927 (60)  
DT Utility  
FS APPLICATION  
LREP Shelley P.M. Fussey, Ph.D., Williams, Morgan & Amerson, P.C., Suite

1100, 10333 Richmond Avenue, Houston, TX, 77042

CLMN Number of Claims: 43

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 9999

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various defined combinations of agents for use in improved anti-vascular **therapies** and coagulative tumor **treatment**. Particularly provided are combined **treatment** methods, and associated compositions, pharmaceuticals, **medicaments**, kits and uses, which together function surprisingly effectively in the **treatment** of vascularized tumors. The invention preferably involves a component or **treatment** step that enhances the effectiveness of **therapy** using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.

L24 ANSWER 4 OF 22 USPATFULL on STN

AN 2003:257253 USPATFULL

TI **Lipopolysaccharide** binding protein derivatives

IN Gazzano-Santoro, Helene, San Bruno, CA, UNITED STATES

Theofan, Georgia, Torrance, CA, UNITED STATES

Trown, Patrick, Danville, CA, UNITED STATES

PA XOMA Technology Ltd., Berkeley, CA (U.S. corporation)

PI US 2003180303 A1 20030925

AI US 2002-131686 A1 20020423 (10)

RLI Continuation of Ser. No. US 1999-280909, filed on 29 Mar 1999, GRANTED, Pat. No. US 6376462 Continuation of Ser. No. US 1997-985446, filed on 5 Dec 1997, ABANDONED Continuation of Ser. No. US 1994-261660, filed on 17 Jun 1994, GRANTED, Pat. No. US 5731415 Continuation-in-part of Ser. No. US 1993-79510, filed on 17 Jun 1993, ABANDONED

DT Utility

FS APPLICATION

LREP MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357

CLMN Number of Claims: 32

ECL Exemplary Claim: 1

DRWN 21 Drawing Page(s)

LN.CNT 2591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel biologically active **lipopolysaccharide** binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize **LPS** and which lack the CD14-mediated immunostimulatory properties of holo-LBP.

L24 ANSWER 5 OF 22 USPATFULL on STN

AN 2003:234579 USPATFULL

TI Vaccine and antitoxin for **treatment** and prevention of C. difficile disease

IN Kink, John A., Madison, WI, United States

Williams, James A., Lincoln, NE, United States

PA Promega Corporation, Madison, WI, United States (U.S. corporation)

PI US 6613329 B1 20030902

AI US 1998-84517 19980526 (9)

RLI Continuation of Ser. No. US 1995-422711, filed on 14 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, now patented, Pat. No. US 5919665 Continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 Continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 Continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193

DT Utility

FS GRANTED

EXNAM Primary Examiner: Kunz, Gary; Assistant Examiner: Turner, Sharon

LREP Medlen & Carroll, LLP  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 48 Drawing Figure(s); 46 Drawing Page(s)  
LN.CNT 11913

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present provides neutralizing antitoxin directed against *C. difficile* toxins. These antitoxins are produced in avian species using soluble recombinant *C. difficile* toxin proteins. The avian antitoxins are designed so as to be orally administrable in **therapeutic** amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the **treatment** of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with *C. difficile* infection. These vaccines are useful for administration to humans and other animals at risk of exposure to *C. difficile* toxins.

=> d 124 10-20 bib ab

L24 ANSWER 10 OF 22 USPATFULL on STN

AN 2003:53682 USPATFULL

TI Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins

IN Mizzen, Lee A., Victoria, CANADA

Chu, N. Randall, Victoria, CANADA

Wu, Huacheng Bill, Victoria, CANADA

PA Stressgen Biotechnologies, Inc., Vancouver, CANADA (non-U.S. corporation)

PI US 6524825 B1 20030225

AI US 2000-498918 20000204 (9)

RLI Continuation of Ser. No. WO 1998-CA246, filed on 20 Mar 1998

PRAI US 1997-54835P 19970805 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Park, Hankyel T.

LREP Fish & Richardson P.C.

CLMN Number of Claims: 100

ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates

and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

L24 ANSWER 11 OF 22 USPATFULL on STN

AN 2002:235983 USPATFULL

TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM

Rott, Jacqueline, Elstree, UNITED KINGDOM

Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority (non-U.S. corporation)

PI US 2002128180 A1 20020912

AI US 2002-82925 A1 20020226 (10)

RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A 371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997, UNKNOWN

PRAI GB 1996-4921 19960308

DT Utility

FS APPLICATION

LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of removing **endotoxin** from **preparation of alpha-1-acid glycoprotein** (orosomucoid) by contact with a finely divided non-toxic **resin** such as **fumed silica**. The invention also relates to a **purification** process for **alpha-1-acid glycoprotein** which includes this **depyrogenation** step, and to the **depyrogenated** product and its clinical uses.

L24 ANSWER 12 OF 22 USPATFULL on STN

AN 2002:221788 USPATFULL

TI Uses of **lipopolysaccharide** binding protein

IN Dedrick, Russell L., Kensington, CA, UNITED STATES

Carroll, Stephen F., Walnut Creek, CA, UNITED STATES

PA XOMA Corporation (U.S. corporation)

PI US 2002119930 A1 20020829

US 2003236187 A9 20031225

AI US 2001-4139 A1 20011023 (10)

RLI Continuation of Ser. No. US 1999-395453, filed on 14 Sep 1999, GRANTED, Pat. No. US 6306824

DT Utility

FS APPLICATION

LREP HONEYWELL INTERNATIONAL INC., 101 COLUMBIA ROAD, P O BOX 2245, MORRISTOWN, NJ, 07962-2245

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 977

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel LBP compositions and **therapeutic** uses for LBP are provided for preventing the adverse effects of exposure to **endotoxin**.

L24 ANSWER 13 OF 22 USPATFULL on STN

AN 2002:109017 USPATFULL

TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM  
Rott, Jacqueline, Elstree, UNITED KINGDOM  
Lewin, David Roger, Elstree, UNITED KINGDOM  
PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)  
PI US 6387877 B1 20020514  
WO 9732893 19970912  
AI US 1999-142348 19990125 (9)  
WO 1997-GB642 19970307  
19990125 PCT 371 date  
PRAI DE 1996-4921 19960308  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed, Abdel A.  
LREP Schwegman, Lundberg, Woessner & Kluth, P.A.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of **removing endotoxin** from **preparations of alpha-1-acid glycoprotein** (orosomucoid) by contact with a finely divided non-toxic **resin** such as **fumed silica**. The invention also relates to a **purification** process for **alpha-1-acid glycoprotein** which includes this deprogenation step, and to the **depyrogenated** product and its clinical uses.

L24 ANSWER 14 OF 22 USPATFULL on STN

AN 2002:102619 USPATFULL  
TI **Endotoxin** binding and neutralizing protein and uses thereof  
IN Wainwright, Norman R., Falmouth, MA, United States  
Novitsky, Thomas J., E. Falmouth, MA, United States  
PA Associates of Cape Cod, Inc., Falmouth, MA, United States (U.S. corporation)  
PI US 6384200 B1 20020507  
AI US 1997-850011 19970501 (8)  
RLI Division of Ser. No. US 1995-476940, filed on 7 Jun 1995, now patented, Pat. No. US 5627266, issued on 6 May 1997 Division of Ser. No. US 1994-264244, filed on 22 Jun 1994, now patented, Pat. No. US 5594113, issued on 14 Jan 1997 Continuation of Ser. No. US 1992-883457, filed on 15 May 1992, now abandoned Continuation-in-part of Ser. No. US 1991-701501, filed on 16 May 1991, now abandoned Continuation-in-part of Ser. No. US 1990-480957, filed on 16 Feb 1990, now abandoned Division of Ser. No. US 1988-210575, filed on 23 Jun 1988, now abandoned  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Gupta, Anish  
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)  
LN.CNT 1219

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Endotoxin** binding/neutralizing proteins capable of binding **endotoxin** in vivo, thereby neutralizing the toxic effect or bioactivity of **endotoxin** which are isolated from a horseshoe crab such as *Limulus polyphemus*, pharmaceutical compositions and pharmaceutical uses of the proteins, a method of **purifying** the proteins and an assay for **endotoxin** based on the proteins, are disclosed.

L24 ANSWER 15 OF 22 USPATFULL on STN

AN 2002:88454 USPATFULL

TI **Lipopolysaccharide** binding protein derivatives  
IN Gazzano-Santoro, Hele{overscore (n)}e, San Bruno, CA, United States  
Theofan, Georgia, Torrance, CA, United States  
Trown, Patrick W., Danville, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 6376462 B1 20020423  
AI US 1999-280909 19990329 (9)  
RLI Continuation of Ser. No. US 1997-985446, filed on 5 Dec 1997, now  
abandoned Continuation of Ser. No. US 1994-261660, filed on 17 Jun 1994,  
now patented, Pat. No. US 5731415 Continuation-in-part of Ser. No. US  
1993-79510, filed on 17 Jun 1993, now abandoned  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Romeo, David S.  
LREP Marshall, Gerstein, & Borun  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 26 Drawing Figure(s); 25 Drawing Page(s)  
LN.CNT 2606

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel biologically active **lipopolysaccharide**  
binding protein (LBP) derivatives including LBP derivative hybrid  
proteins which are characterized by the ability to bind to and  
neutralize **LPS** and which lack the CD14-mediated  
immunostimulatory properties of holo-LBP.

L24 ANSWER 16 OF 22 USPATFULL on STN

AN 2002:21823 USPATFULL

TI PREVENTION AND **TREATMENT** OF VEROTOXIN-INDUCED DISEASE

IN WILLIAMS, JAMES A., LINCOLN, NE, UNITED STATES

BYRNE, LISA MARIE, STOUGHTON, WI, UNITED STATES

PUGH, CHARLES S.G., MADISON, WI, UNITED STATES

PI US 2002012658 A1 20020131

US 6652857 B2 20031125

AI US 1999-334477 A1 19990616 (9)

RLI Continuation of Ser. No. US 1997-816977, filed on 13 Mar 1997, GRANTED,  
Pat. No. US 6080400

DT Utility

FS APPLICATION

LREP KAMRIN T MACKNIGHT, MEDLEN & CARROLL LLP, 220 MONTGOMERY STREET, SUITE  
2200, SAN FRANCISCO, CA, 94104

CLMN Number of Claims: 51

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 5803

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes methods for generating neutralizing  
antitoxin directed against verotoxins. In preferred embodiments, the  
antitoxin directed against these toxins is produced in avian species  
using soluble recombinant verotoxin proteins. This antitoxin is designed  
so as to be administrable in **therapeutic** amounts and may be in  
any form (i.e., as a solid or in aqueous solution). These antitoxins are  
useful in the **treatment** of humans and other animals  
intoxicated with at least one bacterial toxin, as well as for preventive  
**treatment**, and diagnostic assays to detect the presence of toxin  
in a sample.

L24 ANSWER 17 OF 22 USPATFULL on STN

AN 2000:80408 USPATFULL

TI Compositions for the prevention and **treatment** of  
verotoxin-induced disease

IN Williams, James A., Lincoln, NE, United States

Byrne, Lisa Marie, Stoughton, WI, United States

PA Ophidian Pharmaceuticals, Inc., Wisconsin, United States (U.S.  
corporation)



PI US 6080400 20000627  
 AI US 1997-816977 19970313 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-410058, filed on 24 Mar 1995,  
 now abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Devi, S.  
 LREP Medlen & Carroll, LLP  
 CLMN Number of Claims: 2  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Figure(s); 9 Drawing Page(s)  
 LN.CNT 5468  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention includes methods for generating neutralizing  
 antitoxin directed against verotoxins. In preferred embodiments, the  
 antitoxin directed against these toxins is produced in avian species  
 using soluble recombinant verotoxin proteins. This antitoxin is designed  
 so as to be administrable in **therapeutic** amounts and may be in  
 any form (i.e., as a solid or in aqueous solution). These antitoxins are  
 useful in the **treatment** of humans and other animals  
 intoxicated with at least one bacterial toxin, as well as for preventive  
**treatment**, and diagnostic assays to detect the presence of toxin  
 in a sample.

L24 ANSWER 18 OF 22 USPATFULL on STN  
 AN 1999:151185 USPATFULL  
 TI Uses of **lipopolysaccharide** binding protein  
 IN Dedrick, Russell L., Kensington, CA, United States  
 Carroll, Stephen F., Walnut Creek, CA, United States  
 PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
 PI US 5990082 19991123  
 AI US 1997-955660 19971022 (8)  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Borin, Michael  
 LREP Marshall, O'Toole, Gerstein, Murray & Borun  
 CLMN Number of Claims: 3  
 ECL Exemplary Claim: 1  
 DRWN 7 Drawing Figure(s); 7 Drawing Page(s)  
 LN.CNT 1136  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Novel LBP compositions and **therapeutic** uses for LBP are  
 provided for preventing the adverse effects of exposure to  
**endotoxin**.

L24 ANSWER 19 OF 22 USPATFULL on STN  
 AN 1999:75522 USPATFULL  
 TI Vaccine for clostridium botulinum neurotoxin  
 IN Williams, James A., Madison, WI, United States  
 PA Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S.  
 corporation)  
 PI US 5919665 19990706  
 AI US 1995-405496 19950316 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-329154, filed on 25 Oct 1994,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823  
 which is a continuation-in-part of Ser. No. US 1992-985321, filed on 4  
 Dec 1992 which is a continuation-in-part of Ser. No. US 1989-429791,  
 filed on 31 Oct 1989, now patented, Pat. No. US 5196193, issued on 23  
 Mar 1993  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Rabin,  
 Evelyn  
 LREP Medlen & Carroll, LLP

CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Figure(s); 29 Drawing Page(s)  
LN.CNT 9164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant **endotoxin** contamination are provided. The soluble, **endotoxin**-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the **treatment** of humans and other animals at risk of intoxication with clostridial toxin.

L24 ANSWER 20 OF 22 USPATFULL on STN

AN 1998:159467 USPATFULL

TI Methods of inhibiting complement activation

IN Ko, Jone-Long, Sudbury, MA, United States

Higgins, Paul J., Medford, MA, United States

Yeh, C. Grace, Marlborough, MA, United States

PA Cytomed, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 5851528 19981222

AI US 1997-888171 19970703 (8)

RLI Division of Ser. No. US 1994-310416, filed on 22 Sep 1994, now patented, Pat. No. US 5679546 which is a continuation-in-part of Ser. No. US 1993-126596, filed on 24 Sep 1993, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Kemmerer, Elizabeth C.; Assistant Examiner: Romeo, David S.

LREP Fish & Richardson P.C.

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 15 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 1744

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel chimeric proteins comprising a first polypeptide which inhibits complement activation, linked to a second polypeptide which inhibits complement activation, nucleic acids encoding novel chimeric proteins and methods of reducing inflammation with the administration of the chimeric proteins of the invention.

=> d 124 6-9 bib ab

L24 ANSWER 6 OF 22 USPATFULL on STN

AN 2003:213818 USPATFULL

TI Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins

IN Mizzen, Lee A., Victoria, CANADA

Chu, N. Randall, Victoria, CANADA

Wu, Huacheng Bill, Victoria, CANADA

PA Stressgen Biotechnologies, Inc., a British Columbia, Canada corporation (non-U.S. corporation)

PI US 2003148456 A1 20030807

AI US 2002-289760 A1 20021107 (10)

RLI Continuation of Ser. No. US 2000-498918, filed on 4 Feb 2000, GRANTED, Pat. No. US 6524825 Continuation of Ser. No. WO 1998-CA246, filed on 20 Mar 1998, UNKNOWN

PRAI US 1997-54835P 19970805 (60)

DT Utility

FS APPLICATION

LREP LEE CREWS, PH.D., Fish & Richardson P.C., 225 Franklin Street, Boston,

MA, 02110-2804  
CLMN Number of Claims: 44  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 1784

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

L24 ANSWER 7 OF 22 USPATFULL on STN

AN 2003:201388 USPATFULL

TI Combined methods for tumor vasculature coagulation and **treatment**

IN Thorpe, Philip E., Dallas, TX, UNITED STATES

King, Steven W., Rancho Santa Margarita, CA, UNITED STATES

Gottstein, Claudia, Dallas, TX, UNITED STATES

PA Board of Regents, The University of Texas System and Peregrine Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003139374 A1 20030724

AI US 2002-259236 A1 20020927 (10)

PRAI US 2001-325532P 20010927 (60)

DT Utility

FS APPLICATION

LREP Shelley P.M. Fussey, Williams, Morgan & Amerson, P.C., Suite 250, 7676 Hillmont, Houston, TX, 77040

CLMN Number of Claims: 43

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 10003

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various defined combinations of agents for use in improved anti-vascular **therapies** and coagulative tumor **treatment**. Particularly provided are combined **treatment** methods, and associated compositions, pharmaceuticals, **medicaments**, kits and uses, which together function surprisingly effectively in the **treatment** of vascularized tumors. The invention preferably involves a component or **treatment** step that enhances the effectiveness of **therapy** using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.

L24 ANSWER 8 OF 22 USPATFULL on STN

AN 2003:187407 USPATFULL

TI Combined methods for tumor vasculature coaguligand **treatment**  
IN Thorpe, Philip E., Dallas, TX, UNITED STATES  
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES  
Gottstein, Claudia, Dallas, TX, UNITED STATES  
PA Board of Regents, The University of Texas System and Peregrine  
Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2003129193 A1 20030710  
AI US 2002-259227 A1 20020927 (10)  
PRAI US 2001-325532P 20010927 (60)  
DT Utility  
FS APPLICATION  
LREP Shelley P.M. Fussey, Williams, Morgan & Amerson, P.C., Suite 250, 7676  
Hillmont, Houston, TX, 77040  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 10012  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are various defined combinations of agents for use in improved  
anti-vascular **therapies** and coagulative tumor  
**treatment**. Particularly provided are combined **treatment**  
methods, and associated compositions, pharmaceuticals,  
**medicaments**, kits and uses, which together function surprisingly  
effectively in the **treatment** of vascularized tumors. The  
invention preferably involves a component or **treatment** step  
that enhances the effectiveness of **therapy** using targeted or  
non-targeted coagulants to cause tumor vasculature thrombosis.

L24 ANSWER 9 OF 22 USPATFULL on STN  
AN 2003:180305 USPATFULL  
TI Combined compositions for tumor vasculature coaguligand  
**treatment**  
IN Thorpe, Philip E., Dallas, TX, UNITED STATES  
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES  
Gottstein, Claudia, Dallas, TX, UNITED STATES  
PA Board of Regents, The University of Texas System (U.S. corporation)  
PI US 2003124132 A1 20030703  
AI US 2002-259223 A1 20020927 (10)  
PRAI US 2001-325532P 20010927 (60)  
DT Utility  
FS APPLICATION  
LREP Shelley P.M. Fussey, Ph.D., WILLIAMS, MORGAN & AMERSON, P.C., Suite  
1100, 10333 Richmond Avenue, Houston, TX, 77042  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 10025  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are various defined combinations of agents for use in improved  
anti-vascular **therapies** and coagulative tumor  
**treatment**. Particularly provided are combined **treatment**  
methods, and associated compositions, pharmaceuticals,  
**medicaments**, kits and uses, which together function surprisingly  
effectively in the **treatment** of vascularized tumors. The  
invention preferably involves a component or **treatment** step  
that enhances the effectiveness of **therapy** using targeted or  
non-targeted coagulants to cause tumor vasculature thrombosis.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:10:46 ON 29 FEB 2004